Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
432 studies found for:    "Expanded Access" [STUDY-TYPES]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 No longer available Compassionate Use Treatment for a Single Patient With a Custom Made Branched/Fenestrated Endovascular Device for the Treatment of Complex Abdominal Aortic Aneurysm
Condition: Complex Abdominal Aortic Aneurysm
Intervention: Device: Fenerated AAA Endovascular Graft with H&L-B One Shot Introduction System
2 Available An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
Condition: Hemophilia A
Intervention: Biological: Emicizumab
3 Available Axicabtagene Ciloleucel Expanded Access Study
Conditions: Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma;   Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma;   Relapsed/Refractory Transplant Ineligible Transformed Follicular Lymphoma
Intervention: Biological: Axicabtagene Ciloleucel
4 Available An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Condition: Graft-versus-host Disease (GVHD)
Intervention: Drug: Ruxolitinib
5 Available Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC
Conditions: Leukemia;   Bone Marrow Failure Syndrome;   Immunodeficiencies
Intervention: Device: Apha/beta T and CD19+ cell depletion using CliniMACS device
6 Available Expanded Access to VAL-083
Condition: Cancer
Intervention: Drug: VAL-083
7 Available Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma
Condition: Glioma
Intervention: Drug: ONC201
8 Available Single Patient, Compassionate Use of MARGETUXIMAB for the Treatment of HER2+ Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer;   Neoplasm Metastasis
Intervention:
9 Temporarily not available Use of Domperidone for Treatment of Upper Gastrointestinal Disorders
Condition: Gastroparesis
Intervention: Drug: Domperidone
10 Available Lorlatinib - PF-06463922
Condition:
Intervention: Drug: Lorlatinib
11 Available Inotuzumab Ozogamicin - PF-05208773
Condition:
Intervention: Drug: Inotuzumab Ozogamicin
12 Available Expanded Access for Nivolumab (Opdivo)
Condition: Pediatric Cancer
Intervention: Biological: Nivolumab
13 Available Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: Elotuzumab
14 Available Compassionate Use Program For Subcutaneous (SC) Belimumab
Condition: Systemic Lupus Erythematosus
Intervention: Drug: SC belimumab 200 mg
15 Available Expanded Access to Glecaprevir/ Pibrentasvir
Condition: Hepatitis C Virus Infection
Interventions: Drug: glecaprevir;   Drug: pibrentasvir
16 Available Expanded Access to ABT-414
Condition: Cancer
Intervention: Drug: ABT-414
17 Available Expanded Treatment Protocol in Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Genetic: CTL019
18 Available Expanded Access to Veliparib
Condition: Cancer
Intervention: Drug: Veliparib
19 Available Expanded Access to Venetoclax
Conditions: Chronic Lymphocytic Leukemia (CLL);   Multiple Myeloma;   Acute Myeloid Leukemia (AML);   Non-Hodgkin's Lymphoma
Intervention: Drug: Venetoclax
20 Available An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)
Condition: FLT3-mutated Acute Myeloid Leukemia
Intervention: Drug: Midostaurin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.